• Australia's leading medical cannabis manufacturer, outperforming growth forecasts
• Expanding into European and UK markets with significant revenue opportunities
• Developing MDMA and psilocybin-based medicines, with first revenues expected in 2025

Bioxyne Ltd, an Australian pharmaceutical company, has released an investor presentation update showcasing its impressive performance and growth in the medical cannabis market. Over the past 12 months, the company has become the leading manufacturer of medical cannabis in Australia, producing over 1 million finished medicines and 15 million individual pastilles. Bioxyne has also expanded its operations, now working with over 100 B2B clients and achieving a current sales run rate of $3 million per month. The company has 33 registered SKUs in Australia, 18 in the UK, and 16 in Germany. Moving forward, Bioxyne is making significant progress in the European market, with 16 BfArM product registrations submitted and a contracted minimum revenue of $5.6 million for FY2026 from one client. The company is also investing $500,000 in an EU GMP flower packing facility with a target annual capacity of 20 tons. In the UK, Bioxyne is finalizing commercial terms with 10 clinics and pharmacies representing 60,000 patients, with the potential for significant revenue opportunities. Additionally, the company has made progress in the development of MDMA and psilocybin-based medicines, with the first revenues expected in July 2025. Overall, Bioxyne has demonstrated strong operational performance and is well-positioned for continued growth in the medical cannabis and psychedelics markets.

Bioxyne has provided a revenue guidance update for FY2025, revising its previous guidance of $25 million to $28 million, representing a 50% forecast gross margin before sales commissions. The company is targeting continued growth and maintaining profitability metrics.